News

Utrecht, The Netherlands, January 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has selected MCLA-117 as lead candidate for cli...

Utrecht, The Netherlands, December 11, 2012 - Merus B.V., a biopharmaceutical company focused on innovative human antibody therapeutics, today announced the appointment of Setareh van Driel Shamsili, MD, Ph....

Amsterdam, The Netherlands, November 7th 2011 - The grant of EUR 1.5 million is awarded to a multidisciplinary consortium including SomantiX and the VU University Medical Center Amsterdam by the European col...

Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program Nijmegen/Utrecht, the Netherlands - October 15, 2012 - InteRNA Technologies B.V., a d...

UTRECHT - The Netherlands - October 8, 2012 - Merus B.V., a biopharmaceutical company focused on innovative human antibody therapeutics, announced today the full validation of its transgenic MeMo® mouse for...

Amsterdam, The Netherlands - September 6th, 2012 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its patent port...

Utrecht, The Netherlands, June 20, 2012 - Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that it has been granted the first European patent cove...

Utrecht, The Netherlands, June 15, 2012 - Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that Jason Avery has been appointed as Chief Business O...

Nijmegen/Utrecht (the Netherlands) - November 21, 2011 - InteRNA Technologies B.V., a drug discovery and development company engaged in the development of microRNA-based therapeutics for oncology, announces...

Amsterdam, The Netherlands - November 8th, 2011 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has received an innovation cr...

Utrecht (the Netherlands) - InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer. Und...

Leiden, The Netherlands, October 17th, 2011 - ISA Pharmaceuticals, a leader in the development of novel immunotherapeutic products for oncology and infectious diseases, today announced that Professor Jan van...

Leiden, The Netherlands, October 5th , 2011 ISA Pharmaceuticals BV, a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that orphan drug designati...

Utrecht, The Netherlands, September 27, 2011 - Merus announced today that it has completed the construction of a single-light chain transgenic mouse for the generation of therapeutic human monoclonal antibod...

Collaboration to investigate potential of AtuPLEX™ in the development of novel microRNA therapeutics targeting cancer London, UK & Nijmegen/Utrecht, Netherlands, September 12, 2011 - Silence Therapeutics pl...

Amsterdam (the Netherlands) - July 7, 2011 - SomantiX B.V., a biotech company focused on the development of new angiogenesis inhibitors, announces the establishment of its Scientific Advisory Board. Tumor...

Amsterdam, The Netherlands - July 4th, 2011 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has secured key intellectual prop...

Leiden, The Netherlands, May 26th, 2011 - ISA Pharmaceuticals B.V., a private, clinical stage company and leader in the development of immunotherapeutic products for oncology and infectious diseases, and Tra...

Utrecht, The Netherlands and Zurich, Switzerland, May 16 2011 - Merus BV and ChromaCon AG announced today the award of a EUREKA Eurostars grant with a total budget of €1.8 million to discover and develop bis...